Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Valencia Website

Julio C. Valencia, M.D.

Selected Publications

1)  Valencia JC, Hearing V.
Petrescu S, eds.
The Role of Glycosylation in the Control of Processing and Cellular Transport of the Functional Amyloid PMEL17. In: Glycosylation.
Rijeka, Croatia: InTech; 2012. p. 327-350 [Book Chapter]
2)  Hu ZZ, Valencia JC, Huang H, Chi A, Shabanowitz J, Hearing VJ, Appella E, Wu C.
Comparative Bioinformatics Analyses and Profiling of Lysosome-Related Organelle Proteomes.
Int J Mass Spectrom. 259: 147-160, 2007.
3)  Valencia JC, Rouzaud F, Julien S, Chen KG, Passeron T, Yamaguchi Y, Abu-Asab M, Tsokos M, Costin GE, Yamaguchi H, Jenkins LM, Nagashima K, Appella E, Hearing VJ.
Sialylated core 1 O-glycans influence the sorting of Pmel17/gp100 and determine its capacity to form fibrils.
J. Biol. Chem. 282: 11266-80, 2007.
4)  Ando H, Wen ZM, Kim HY, Valencia JC, Costin GE, Watabe H, Yasumoto K, Niki Y, Kondoh H, Ichihashi M, Hearing VJ.
Intracellular composition of fatty acid affects the processing and function of tyrosinase through the ubiquitin-proteasome pathway.
Biochem. J. 394: 43-50, 2006.
5)  Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD, Hearing VJ, Gottesman MM.
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.
Proc. Natl. Acad. Sci. U.S.A. 103: 9903-7, 2006.
6)  Valencia JC, Hoashi T, Pawelek JM, Solano F, Hearing VJ.
Pmel17: controversial indeed but critical to melanocyte function.
Pigment Cell Res. 19: 250-2; author reply 253-7, 2006.
7)  Chi A, Valencia JC, Hu ZZ, Watabe H, Yamaguchi H, Mangini NJ, Huang H, Canfield VA, Cheng KC, Yang F, Abe R, Yamagishi S, Shabanowitz J, Hearing VJ, Wu C, Appella E, Hunt DF.
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes.
J. Proteome Res. 5: 3135-44, 2006.
8)  Rouzaud F, Costin GE, Yamaguchi Y, Valencia JC, Berens WF, Chen KG, Hoashi T, Böhm M, Abdel-Malek ZA, Hearing VJ.
Regulation of constitutive and UVR-induced skin pigmentation by melanocortin 1 receptor isoforms.
FASEB J. 20: 1927-9, 2006.
9)  Valencia JC, Watabe H, Chi A, Rouzaud F, Chen KG, Vieira WD, Takahashi K, Yamaguchi Y, Berens W, Nagashima K, Shabanowitz J, Hunt DF, Appella E, Hearing VJ.
Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes.
J. Cell. Sci. 119: 1080-91, 2006.
10)  Valencia JC, Pacheco-Rodriguez G, Carmona AK, Xavier J, Bruneval P, Riemenschneider WK, Ikeda Y, Yu ZX, Ferrans VJ, Moss J.
Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis.
Am. J. Respir. Cell Mol. Biol. 35: 40-7, 2006.
11)  Berens W, Van Den Bossche K, Yoon TJ, Westbroek W, Valencia JC, Out CJ, Marie Naeyaert J, Hearing VJ, Lambert J.
Different approaches for assaying melanosome transfer.
Pigment Cell Res. 18: 370-81, 2005.
12)  Costin GE, Valencia JC, Wakamatsu K, Ito S, Solano F, Milac AL, Vieira WD, Yamaguchi Y, Rouzaud F, Petrescu AJ, Lamoreux ML, Hearing VJ.
Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein.
Biochem. J. 391: 249-59, 2005.
13)  Chen KG, Szakács G, Annereau JP, Rouzaud F, Liang XJ, Valencia JC, Nagineni CN, Hooks JJ, Hearing VJ, Gottesman MM.
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes.
Pigment Cell Res. 18: 102-12, 2005.
14)  Yasumoto K, Watabe H, Valencia JC, Kushimoto T, Kobayashi T, Appella E, Hearing VJ.
Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment.
J. Biol. Chem. 279: 28330-8, 2004.
15)  Ando H, Watabe H, Valencia JC, Yasumoto K, Furumura M, Funasaka Y, Oka M, Ichihashi M, Hearing VJ.
Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase: a new aspect of ubiquitin-proteasome function.
J. Biol. Chem. 279: 15427-33, 2004.
16)  Costin GE, Vieira WD, Valencia JC, Rouzaud F, Lamoreux ML, Hearing VJ.
Immortalization of mouse melanocytes carrying mutations in various pigmentation genes.
Anal. Biochem. 335: 171-4, 2004.
17)  Watabe H, Valencia JC, Yasumoto K, Kushimoto T, Ando H, Muller J, Vieira WD, Mizoguchi M, Appella E, Hearing VJ.
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity.
J. Biol. Chem. 279: 7971-81, 2004.
18)  Rouzaud F, Annereau JP, Valencia JC, Costin GE, Hearing VJ.
Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist.
FASEB J. 17: 2154-6, 2003.
19)  Kushimoto T, Valencia JC, Costin GE, Toyofuku K, Watabe H, Yasumoto K, Rouzaud F, Vieira WD, Hearing VJ.
The Seiji memorial lecture: the melanosome: an ideal model to study cellular differentiation.
Pigment Cell Res. 16: 237-44, 2003.
20)  Costin GE, Valencia JC, Vieira WD, Lamoreux ML, Hearing VJ.
Tyrosinase processing and intracellular trafficking is disrupted in mouse primary melanocytes carrying the underwhite (uw) mutation. A model for oculocutaneous albinism (OCA) type 4.
J. Cell. Sci. 116: 3203-12, 2003.
21)  Toyofuku K, Valencia JC, Kushimoto T, Costin GE, Virador VM, Vieira WD, Ferrans VJ, Hearing VJ.
The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase.
Pigment Cell Res. 15: 217-24, 2002.
22)  Valencia JC, Matsui K, Bondy C, Zhou J, Rasmussen A, Cullen K, Yu ZX, Moss J, Ferrans VJ.
Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis.
J. Investig. Med. 49: 421-33, 2001.
23)  Toyofuku K, Wada I, Valencia JC, Kushimoto T, Ferrans VJ, Hearing VJ.
Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins.
FASEB J. 15: 2149-61, 2001.
24)  Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, Riemenschn W, Matsui K, Travis WD, Moss J.
Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features.
Journal of Nippon Medical School = Nihon Ika Daigaku zasshi. 67: 311-29, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 11/2/2012.